T cell engaging bispecific antibodies targeting CD33 IgV and IgC domains for the treatment of acute myeloid leukemia.
T cell engaging bispecific antibodies targeting CD33 IgV and IgC domains for the treatment of acute myeloid leukemia.
复制标题
DOI:
10.1136/jitc-2021-002509
复制
发表时间:
2021-05
影响因子:
10.9
通讯作者:
Cheung NV
中科院分区:
文献类型:
--
作者:
Hoseini SS;Vadlamudi M;Espinosa-Cotton M;Tran H;Feng Y;Guo HF;Xu H;Cheung I;Cheung NV
Acute myeloid leukemia (AML) remains one of the most challenging hematological malignancies. Despite progress in therapeutics, majority of patients succumb to this neoplasm. CD33 is a proven therapeutic target, given its expression on most AML cells. Almost all anti-CD33 antibodies target the membrane distal immunoglobulin V (IgV) domain of the CD33 extracellular domain. In this manuscript, we present data on three bispecific antibodies (BsAbs) against the CD33 IgV and membrane proximal immunoglobulin C (IgC) domains. We use in vitro binding and cytotoxicity assays to show the effect of these BsAbs on AML cell lines. We also use immunodeficient mice-bearing leukemias from cell lines and patient-derived xenografts to show the effect of these BsAbs in vivo. In vitro, the IgV-targeting BsAb had higher binding to AML cell lines using flow cytometry and delivered more potent cytotoxicity in T-cell-dependent cytotoxicity assays; importantly, the IgC domain-targeting outperformed the IgV domain-targeting BsAb in medullary and extramedullary leukemia animal models. These data support further clinical development of this BsAb for first-in-human phase I clinical trial.
登录
查看更多内容
影响因子:
7.5
作者:
Nair-Gupta, Priyanka;Diem, Michael;Gaudet, Francois
通讯作者:
Gaudet, Francois
影响因子:
45.3
作者:
Lamba, Jatinder K.;Chauhan, Lata;Meshinchi, Soheil
通讯作者:
Meshinchi, Soheil
影响因子:
7.5
作者:
Hoseini, Sayed Shahabuddin;Guo, Hongfen;Cheung, Nai-Kong V.
通讯作者:
Cheung, Nai-Kong V.
影响因子:
1.1
作者:
Hao, Tran Kiem;Ha, Chau Van;Hiep, Pham Nhu
通讯作者:
Hiep, Pham Nhu
影响因子:
10.1
作者:
Xu, Hong;Cheng, Ming;Cheung, Nai-Kong V.
通讯作者:
Cheung, Nai-Kong V.